Carcinoid Tumors Clinical Trial
Official title:
An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors
Study evaluating SOM230 in patients with metastatic carcinoid tumors
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT00580320 -
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
|
Phase 1 | |
| Completed |
NCT02575300 -
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02441088 -
Theranostics: 68GaDOTATOC and 90YDOTATOC
|
Phase 2 | |
| Terminated |
NCT00227136 -
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
|
Phase 3 | |
| Terminated |
NCT00947167 -
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
|
Phase 2 | |
| Terminated |
NCT02177773 -
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02795858 -
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
|
Phase 2 | |
| Terminated |
NCT02859064 -
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
|
Phase 2 | |
| Active, not recruiting |
NCT01731925 -
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
|
Phase 2 | |
| Completed |
NCT01619865 -
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01253161 -
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
|
Phase 2 | |
| Terminated |
NCT02359500 -
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
|
Phase 1 | |
| No longer available |
NCT01980732 -
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
|
N/A | |
| Not yet recruiting |
NCT01373736 -
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
|
Phase 3 |